🔹 The RHU DESTINATION 2024 is a multidisciplinary partnership that aims to revolutionise the care of patients through better identification and management of chronic thromboembolic pulmonary hypertension, as well as by improving the quality of care and developing a “treat to cure” approach.
🔹 Coordinated by AP-HP, Assistance Publique – Hôpitaux de Paris, and bringing together public and private partners (Université Paris-Saclay, INSERM, Hôpital Marie-Lannelongue, Groupe Hospitalier Paris-Saint Joseph, GE HealthCare, Janssen), the RHU DESTINATION 2024 project aims to promote early diagnosis, assess severity, and treat this disease.
🔹 This work has received state support managed by the National Research Agency under the future investment program integrated into France 2030, with the reference ANR-18-RHUS-0006.
This video on chronic thromboembolic pulmonary hypertension (CTEPH) was developed as part of the RHU DESTINATION 2024 project in France. See more at this link on the RHU DESTINATION 2024 YouTube channel.
See also our previous article titled “Patient Perspectives in the French RHU DESTINATION 2024 project on Chronic Thromboembolic Pulmonary Hypertension (CTEPH) Management” here